KZR · Insider Trading
Kezar Life Sciences, Inc. Common Stock
Every open-market purchase and sale reported by KZR officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-11 | Mark C. Schiller | Chief Operating Officer | U | −2,739 | — |
| 2026-05-11 | Pichi Luo Chiang | SVP, Corporate Controller | U | −2,711 | — |
| 2026-05-11 | Michael Kauffman | Director | U | −6,369 | — |
| 2026-05-11 | Franklin M Berger | Director | U | −89,069 | — |
| 2026-05-11 | Christopher J. Kirk | CEO | U | −43,134 | — |
| 2026-05-11 | Marc Belsky | Chief Financial Officer | U | −1,738 | — |
| 2026-05-11 | Graham K Cooper | Director | D | −27,709 deriv. | — |
| 2026-05-11 | Elizabeth Garner | Director | D | −21,368 deriv. | — |
| 2026-05-11 | Courtney Wallace | Director | D | −21,300 deriv. | — |
| 2026-05-11 | John Franklin Fowler | Director | U | −43,611 | — |
| 2026-05-11 | Micki Klearman | Director | D | −23,900 deriv. | — |
| 2025-07-03 | Pichi Luo Chiang | SVP, Corporate Controller | Sell | −264 | −$1.13K |
| 2025-07-03 | Mark C. Schiller | Chief Operating Officer | Sell | −561 | −$2.40K |
| 2025-07-01 | Zung Phuong To | Chief Development Officer | A | +7,000 deriv. | — |
| 2025-06-23 | Franklin M Berger | Director | A | +5,000 deriv. | — |
| 2025-06-23 | Micki Klearman | Director | A | +5,000 deriv. | — |
| 2025-06-23 | Courtney Wallace | Director | A | +5,000 deriv. | — |
| 2025-06-23 | Graham K Cooper | Director | A | +5,000 deriv. | — |
| 2025-06-23 | Michael Kauffman | Director | A | +5,000 deriv. | — |
| 2025-06-23 | Elizabeth Garner | Director | A | +5,000 deriv. | — |
| 2025-06-23 | John Franklin Fowler | Director | A | +5,000 deriv. | — |
| 2025-04-01 | Marc Belsky | Chief Financial Officer | A | +4,800 deriv. | — |
| 2025-04-01 | Mark C. Schiller | Chief Legal Officer | A | +4,800 deriv. | — |
| 2025-03-05 | Mark C. Schiller | Chief Legal Officer | A | +7,200 deriv. | — |
| 2025-03-05 | Marc Belsky | Chief Financial Officer | A | +7,200 deriv. | — |
| 2025-02-14 | John Franklin Fowler | Director | A | +5,000 deriv. | — |
| 2025-01-13 | Mark C. Schiller | Chief Legal Officer | A | +24,500 deriv. | — |
| 2025-01-13 | Christopher J. Kirk | CEO | A | +120,000 deriv. | — |
| 2025-01-13 | Marc Belsky | Chief Financial Officer | A | +24,500 deriv. | — |
| 2024-07-26 | Mark C. Schiller | Chief Legal Officer | Sell | −6,688 | −$3.88K |
| 2024-06-21 | Graham K Cooper | Director | A | +50,000 deriv. | — |
| 2024-06-21 | Elizabeth Garner | Director | A | +50,000 deriv. | — |
| 2024-06-21 | Micki Klearman | Director | A | +50,000 deriv. | — |
| 2024-06-21 | Michael Kauffman | Director | A | +50,000 deriv. | — |
| 2024-06-21 | Franklin M Berger | Director | A | +50,000 deriv. | — |
| 2024-06-21 | Courtney Wallace | Director | A | +50,000 deriv. | — |
| 2024-01-09 | Marc Belsky | Chief Financial Officer | A | +295,000 deriv. | — |
| 2024-01-09 | Nicholas Michael Mordwinkin | Chief Business Officer | A | +275,000 deriv. | — |
| 2023-11-09 | Christopher J. Kirk | CEO | A | +875,000 deriv. | — |
| 2023-08-17 | Morningside Venture Investments Ltd | 10%+ Owner | G | −3,500,000 | — |
| 2023-07-26 | Noreen Henig | Chief Medical Officer | MIXED | — | — |
| 2023-07-26 | Franklin M Berger | Director | MIXED | — | — |
| 2023-07-26 | Courtney Wallace | Director | MIXED | — | — |
| 2023-07-26 | Christopher J. Kirk | Director | MIXED | — | — |
| 2023-07-26 | Michael Kauffman | Director | MIXED | — | — |
| 2023-07-26 | Marc Belsky | Chief Financial Officer | MIXED | — | — |
| 2023-07-26 | Nicholas Michael Mordwinkin | Chief Business Officer | MIXED | +100,000 deriv. | — |
| 2023-07-26 | Micki Klearman | Director | MIXED | — | — |
| 2023-07-26 | Graham K Cooper | Director | MIXED | — | — |
| 2023-07-26 | John Franklin Fowler | CEO | MIXED | — | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the KZR quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.